TMates vs Brello: Flat $199 vs Unverified Pricing — Quick Verdict
Quick verdict: TMates offers a clear, flat $199/month semaglutide program with 24/7 U.S. doctor access and U.S.-formulated compounded medication; Brello’s pricing, eligibility, pharmacy and state coverage details were not verified and are subject to clinician review.
TMates vs Brello: primary differences at a glance
This comparison focuses on five distinctive differences supported by the source evidence: pricing model and transparency, clinician access, medication sourcing and regulatory notes, state coverage and availability, and how verifiable each provider’s public details are. The primary keyword TMates vs Brello appears throughout to keep the comparison clear.
1. Pricing model and transparency
TMates: The source lists a flat $199/month price, advertised as the same price at every dose with no step-up fees. TMates displays additional package price examples and emphasizes a direct-pay model in some captured text but also shows multiple month-package figures on landing-page captures.
Brello: Pricing and full cost details were not verified on the captured affiliate landing page. The long headline for Brello notes pricing and eligibility are subject to the live offer, indicating costs are not published or confirmed in the captured evidence.
2. Clinician access and supervision
TMates: The source repeatedly states TMates provides 24/7 access to U.S.-based doctors, not just messaging support, and includes virtual check-in appointments for ongoing oversight.
Brello: The captured evidence indicates treatment is available only when a licensed clinician determines it is medically appropriate, but no further details about access model or hours were captured.
3. Medication sourcing, formulation and regulatory notes
TMates: Source claims medications are formulated in U.S.-based facilities and describes clinically dosed compounded semaglutide. The evidence includes the regulatory note that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality; that qualifier is preserved in the source material.
Brello: The captured evidence states that when compounded medications are offered they are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. No further medication formulation or pharmacy sourcing details were captured for Brello.
4. State coverage and availability
TMates: The source explicitly states licensed coverage in all 50 states and that the platform ships to most states, with availability based on medical eligibility.
Brello: State coverage and availability were not published or could not be verified on the captured landing page. The long bullets note that pricing, eligibility, pharmacy, state coverage and renewal terms may change.
5. Public verifiability and captured evidence
TMates: Multiple captured landing-page statements and a FAQ were available and cited, including explicit pricing, features and availability notes. The site evidence included examples and claims about acceptance of insurance in captured FAQ text with qualifiers.
Brello: The capture failed to return readable evidence for pricing and features. The browser verification notes navigation timed out and details were listed as not verified or not published on the captured affiliate landing page.
| Criteria | TMates | Brello |
|---|---|---|
| Starting price | $199/month flat at every dose | Not verified |
| Price transparency | Flat-rate model; examples captured on landing page | Pricing subject to live offer; not published in capture |
| Clinician access | 24/7 U.S.-based doctor access; virtual check-ins | Treatment subject to licensed clinician review; access model not captured |
| Medication formulation | Clinically dosed compounded semaglutide; formulated in U.S. facilities | Compounded medications may be offered; sourcing not verified |
| Regulatory note | Compounded medications are not FDA-approved and not reviewed by FDA | Compounded medications are not FDA-approved and not reviewed by FDA |
| State coverage | Licensed in all 50 states; ships to most states, availability based on medical eligibility | State coverage not verified and may change |
How these differences affect you
If you prioritize a published flat-rate price with explicit claims of 24/7 U.S. physician access and U.S.-formulated compounded medication, TMates is supported by the captured evidence. If you need to confirm price, pharmacy, state eligibility or renewal terms before enrolling, the captured evidence recommends verifying Brello’s live offer and clinician review because those details were not published in the capture.
Confirm TMates program details
Final comparison and recommendation
In this TMates vs Brello comparison, TMates is the more verifiable option in the captured evidence: it lists a flat $199/month pricing model, 24/7 U.S. doctor access, U.S.-formulated compounded semaglutide, and captured landing-page detail about availability and packaging. Brello’s captured affiliate landing page did not verify pricing, eligibility, pharmacy or state coverage and notes that pricing and eligibility are subject to the live offer and clinician review.
Choose TMates if…
You want a published flat $199/month semaglutide program with 24/7 access to U.S.-based doctors, U.S.-formulated compounded medication, and captured landing-page detail supporting those claims.
Choose Brello if…
You prefer to confirm pricing, eligibility, pharmacy and state availability directly with a provider whose details are subject to clinician review and live offer terms. The captured evidence explicitly advises verifying those items with Brello before enrollment.
This article used only the supplied captured evidence for the TMates vs Brello comparison. All qualifiers and regulatory notes from the sources were preserved.
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →More comparisons
